
Combination therapy with a lower-intensity statin and bile acid sequestrant or ezetimibe lowered LDL cholesterol similar to or better than higher-intensity statin monotherapy among patients with high risk for atherosclerotic cardiovascular disease (ASCVD), according to a study published February 11 online in the Annals of Internal Medicine.